Hemochromatosis/Iron Overload Therapeutics – Pipeline Analysis, Clinical Trials & Results and other Developments: P&S Market Research

NEW YORK, April 09, 2018 -- According to the new research report published by P&S Market Research, Hyperlipidemia therapeutics currently exhibits a pipeline with nine drug candidates, Hemochromatosis or iron overload refer to the accumulation of excessive iron in the body. Iron chelation therapy is needed to remove this excess iron from the body. Hemochromatosis may be caused due to genetic disorders or acquired by multiple blood transfusions or consuming high levels of supplemental iron. High levels of iron in the body may damage the vital organs in the body. 

According to the research findings, a majority of the drug candidates for the treatment of hemochromatosis are being developed to be administered by the subcutaneous route, which facilitates the absorption of the drug as iron chelator drugs such as deferoxamine, that are poorly absorbed from the gastrointestinal tract.

Request to Get the Sample Pages: https://www.psmarketresearch.com/market-analysis/iron-overload-therapeutics-pipeline/report-sample

As of now, there are three marketed iron chelator drugs available for the treatment of hemochromatosis namely; Deferasirox, Deferoxamine and Deferiprone. Limited competition gives companies investing in the hemochromatosis therapeutics pipeline an opportunity to gain market share. Thus, driving the growth of the hemochromatosis therapeutics pipeline.

Access Report Summary with Detailed TOC on "Hemochromatosis/Iron Overload Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" at: https://www.psmarketresearch.com/market-analysis/iron-overload-therapeutics-pipeline

Hemochromatosis most of the times develops as a hereditary disease. Therefore, it has been observed that the companies are developing drug candidates that suppresses the expression of genes. For instance, ALN-TMP by Alnylam Pharmaceuticals Inc. is under the Pre-Clinical phase of development for the treatment of hemochromatosis. The drug candidate is a Tmprss6 gene suppressor being developed using RNA interference (RNAi) technology.

Some of the key players involved in the development of hemochromatosis therapeutics include La Jolla Pharmaceutical Company, Silence Therapeutics plc, and Shire Plc.

More latest reports by P&S Market Research

Peanut Allergy Therapeutics Pipeline Analysis - https://www.psmarketresearch.com/market-analysis/peanut-allergy-therapeutics-pipeline-analysis

Urinary Tract Infections (UTIs) Therapeutics Pipeline Analysis  - https://www.psmarketresearch.com/market-analysis/utis-therapeutics-pipeline

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research-based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: [email protected]

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook